Evidence map›Paper›PMID 33230582›Full record

SynthesisHeart failure reviews2021

Cost-effectiveness analysis of mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation: a systematic review.

Aziz Rezapour, Samad Azari, Jalal Arabloo, Hamid Pourasghari, Masoud Behzadifar, Vahid Alipour, Negar Omidi, Saeed Sadeghian, Hassan Aghajani, Nicola Luigi Bragazzi

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Charting the Course for Careers in Interventional Heart Failure: Training, Challenges, and Future Directions.Journal of the Society for Cardiovascular Angiography & Interventions · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aziz RezapourHealth Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
Samad AzariHealth Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. Samadazari1010@gmail.com.
Jalal ArablooHealth Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
Hamid PourasghariHospital Management Research Center, Iran University of Medical Sciences, Tehran, Iran.
Masoud BehzadifarSocial Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
Vahid AlipourHealth Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
Negar OmidiDepartment of Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Saeed SadeghianDepartment of Interventional Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Hassan AghajaniDepartment of Interventional Cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Nicola Luigi BragazziLaboratory for Industrial and Applied Mathematics (LIAM), Department of Mathematics and Statistics, York University, Toronto, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the cost-effectiveness of mitral valve repair with the MitraClip delivery system for patients with mitral regurgitation and heart failure, a systematic literature search was conducted in various electronic databases to January 3, 2020. Eligibility criteria are the population (patients with mitral regurgitation (MR)), intervention (transcatheter mitral valve repair using the MitraClip), comparator (conventional medical treatment), outcomes, and designs (Model-based or trial-based full economic evaluations).The quality of included studies was assessed using the CHEERS checklist. Mortality and survival rate, quality-adjusted life year (QALY), life years gained (LYG), total cost, and the incremental cost-effectiveness ratio (ICER) regarding the use of MitraClip System were considered as the key outcomes. Eight articles were eligible for full-text assessment. Ultimately, a total of seven studies were considered in the current systematic review. Results demonstrated that MitraClip reduces mortality rate and increases survival rate. The mortality rate at 1 year and 10 years was 16.7% versus 29.77% and 70.9% versus 98.8%, respectively. Total cost data based on 2019 USD show that the MitraClip has the highest cost in the USA ($121,390) and the lowest cost in Italy ($33,062). The results showed that in all selected countries, willingness-to-pay (WTP) thresholds are upper than the cost per QALY; also, the highest ICER for the MitraClip is in the USA ($55,600/QALY) and the lowest in Italy ($10,616/QALY). To conclude, evidence from this systematic review suggests that MitraClip Delivery System improved both life expectancy and QALY compared with medical treatment in patients at high surgical risk and it was also a cost-effective treatment option for patients with mitral regurgitation.

Indexed as

Cardiac Surgical ProceduresHeart Valve Prosthesis ImplantationMitral Valve InsufficiencyCost-Benefit AnalysisHumansMitral ValveQuality-Adjusted Life YearsTreatment OutcomeCost-effectivenessMitraClipMitral regurgitationMitral valve repairSystematic review

Identifiers

PMID33230582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.